ATAI Hisse Senedi Fiyat Grafiği
ATAI Finansal
AtaiBeckley Inc
$4.58
9.83%
$0.41
Kapanışta: Jun 25, 16:00:00 GMT-4
$4.54
-0.87%
$-0.04
Ön Piyasa: Jun 26, 09:24:10 GMT-4
Geri
AtaiBeckley Inc (ATAI) Finansal
Gelir
Bilanço
Nakit akışı
Yıllık
Çeyrek yıllık
ATAI Gelir
Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Follow-Up Questions
AtaiBeckley Inc'in temel mali tabloları nelerdir?
ATAI'ün temel finansal oranları nelerdir?
AtaiBeckley Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?
AtaiBeckley Inc kârlı mı?
AtaiBeckley Inc'in herhangi bir yükümlülüğü var mı?
AtaiBeckley Inc'in tedavüldeki hisse sayısı kaçtır?
Önemli İstatistikler
Önceki Kapanış
$4.17
Açılış fiyatı
$4.15
Günün Aralığı
$4.15 - $4.81
52 haftalık aralık
$2 - $6.75
İşlem hacmi
10.9M
Ort.Hacim
5.4M
Dividend yield
--
EPS (TTM)
-2.23
Piyasa Değeri
$1.6B
ATAI nedir?
Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2021-06-18. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The firm is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.
